- Methodology
- Open Access
Isobologram analysis of triple therapies
- Maximilian Niyazi^{1}Email author and
- Claus Belka^{1}
https://doi.org/10.1186/1748-717X-1-39
© Niyazi and Belka; licensee BioMed Central Ltd. 2006
- Received: 28 June 2006
- Accepted: 17 October 2006
- Published: 17 October 2006
Abstract
New concepts in radiation oncology are based on the concept that combinations of irradiation and molecular targeted drugs can yield synergistic or at least additive effects. Up to now the combination of two treatment modalities has been tested in almost all cases. Similar to conventional anti-cancer agents, the efficacy of targeted approaches is also subject to predefined resistance mechanisms. Therefore, it seems reasonable to speculate that a combination of more than two agents will ultimately increase the therapeutic gain. No tools for a bio-mathematical evaluation of a given degree of interaction for more than two anti-neoplastic agents are currently available.
The present work introduces a new method for an evaluation of triple therapies and provides some graphical examples in order to visualize the results.
Keywords
- Radiation Oncology
- Triple Therapy
- Combination Index
- Response Additivity
- Molecular Target Drug
Background
Many mathematical approaches have been described in order to determine the level of interaction of two agents. In this regard, isobologram analysis was developed and described 30 years ago and is still the most popular tool for this question [1, 8]. Basically, isobologram analyses are an approach to represent zero-interaction curves of two agents. However, classical isobologram analyses are quite resource intensive and therefore a widespread use has never been adopted.
Although the combination of two agents was effective in many clinical settings, a combination of three or more treatment principles is even more realistic.
In case of radiation oncology it has been shown that the inhibition of EGF-R in combination with radiation using the C225 antibody was effective in terms of local control and survival [4]. However, cis-platinum based radiochemotherapy represents the current standard approach for advanced head and neck cancer. Currently the combination of radiation, cis-platinum and C225 is tested clinically while still lacking a complete preclinical evaluation of the combined therapy [7].
Although targeted agents are clearly effective [6], like for conventional agents the long term efficacy is hampered by specific resistance mechanisms. Therefore it seems to be likely that in the future combinations of distinct and/or interactive targeted drugs will be used in clinical settings.
The present work provides a new mathematical formalism to analyse the level of interaction of three treatment approaches based on a reduced scale data set.
Theoretical background
Before introducing any mathematical detail, it is of crucial importance to define the terms used within this paper: The semantic definition of synergy describes an interaction that is more effective than the sum of the single effects (known by the famous holistic saying "the whole is more than the sum of its parts"). Therefore the term synergy or "supra-additivity" describes situations where the combination of agents acts more than additive [2].
The two classical definitions of additivity go back to Loewe [5] and Bliss [3]. Bliss developed the model of response additivity which is also called the criterion of Bliss independence. These definitions are not only formal thoughts but do have some practical implications [8] which are especially important in the field of radiation oncology. Response additivity means that we assume statistical independence which leads to a pure addition of the effects. In contrast, dose-additivity assumes that the agents behave like simple dilutions and act without self-interaction. In this case it has become popular to talk of zero-interactive responses.
For this purpose Berenbaum developed the following formula:
$\sum _{\text{j}}\frac{{\text{d}}_{\text{j}}}{{\text{D}}_{\text{j}}}}=1\text{}[1]$
where d_{i} is the actual dose (concentration) of the individual agents in a combination and D_{ i }is the dose (concentration) of the agents that individually would produce the same effect as the individual compounds in the combination [1].
By handling linear dose-response-curves one only gets a straight line of additivity which divides the plane into the areas "supra-additive" and "infra-additive".
As one usually considers dose-response-relationships that are non-linear, these two concepts will lead (in the case of two agents/modalities) to an envelope of additivity.
If one assumes a quadratic dose-response relationship for one of the agents (therapy 1) and a linear relationship for a less effective drug (therapy 2) and if one furthermore needs one dose unit of therapy 1 to obtain 10% of the maximum effect (E_{max}) and four dose units of therapy 2 for the same effect, a combination would yield (in the strict response additive case) 20%. In the case of Loewe-additivity this would lead to the following: therapy 2 yields the same like one unit of therapy 1. So the effect would be the same as for two units of therapy 1, namely 40%!
Formal definitions
Now one has to focus on the effect of the single agents. The effect can e. g. be the rate of apoptosis, the amount of dead cells or something similar. The following theory can readily be modified and is completely analogous if one measures surviving fractions. In this case -ln(SF) has to be regarded as the effect where the logarithm is a contribution to the definition of the suriving fraction; this means that surviving fractions are multiplicatively connected while the natural logarithms are additive.
In order to describe the relationship mathematically, the following notation is introduced:
y_{j} = f_{j} (x_{j}), j ∈ {1, 2, 3},
where y denotes the effect and x the dose/concentration of XRT or the drug (in the following the term "dose" is used for both concepts). The functions f_{j} should be continuous and invertable (i. e. bijective). The inverse functions will be denoted by f^{-1}_{j}.
Let d_{j} be the dose of the jth modality in the triple therapy. Therapies will be denoted as (d_{1}|d_{2}|d_{3}); d_{1} relates to the concentration of a hypothetical agent A [μg/ml] (the units are suppressed during the calculations), d_{2} is the concentration of another agent B [nM] and d_{3} denotes the dose of (X)RT [Gy].
Concept
First the surface of strict response additivity will be introduced. It is the surface that contains all combinations which would produce an effect that equals the effect of the triple therapy (the corresponding dose is called isoeffect-dose or in brief isodose). It is denoted by "i". The first formula may thus be written as
$\sum _{\text{j}=1}^{3}{\text{f}}_{\text{j}}\left({\text{x}}_{\text{j}}\right)}=\text{i}\text{}[2]$
which represents a three-dimensional surface in space.
The presented semantic definitions furthermore lead to the following seven equations:
f^{-1}_{3}(f_{1}(x_{1})) + f^{-1}_{3}(f_{2}(x_{2})) + x_{3} = f^{-1}_{3}(i) [3]
f^{-1}_{3}(f_{2}(f^{-1}_{2}(f_{1}(x_{1})) + x_{2})) + x_{3} = f^{-1}_{3}(i) [4]
f^{-1}_{3}(f_{1}(f^{-1}_{1}(f_{2}(x_{2})) + x_{1})) + x_{3} = f^{-1}_{3}(i) [5]
f_{2}(f^{-1}_{2}(f_{1}(x_{1})) + x_{2}) + f_{3}(x_{3}) = i [6]
f_{1}((f^{-1}_{1}(f_{2}(x_{2})) + x_{1}) + f_{3}(x_{3}) = i [7]
f_{3} ^{-1}(f_{1}(x_{1}) + f_{2}(x_{2})) + x_{3} = f^{-1}_{3}(i) [8]
f_{3}(f^{-1}_{3}(f_{1}(x_{1})) + f^{-1}_{3}(f_{2}(x_{2}))) + f_{3}(x_{3}) = i [9]
Most of these equations use a mixed definition for "additivity" namely dose (or Loewe) and response additivity as mentioned above.
Cyclic permutation of these seven equations leads to the other 14 equations.
By further investigation it can be shown that these overall 22 equations are complete which would be beyond the scope of this paper.
For practical use it will be sufficient to examine the two outer surfaces which contain the "volume of additivity" and to determine where the "point of therapy" is located. As shown later, it is not evident what these two surfaces are.
Example
After considering the general purpose of isobologram analysis, the following attempt is used to demonstrate a special example:
f_{j} (x_{j}) = a_{j} ln x_{j} + b_{j}, j ∈ {1, 2}, f_{3} (x_{3}) = a_{3} x_{3} + b_{3} [10]
In this notation f_{3} denotes the effect of (X)RT and a_{j}, b_{j} are parameters to be determined from the experiment. The "effect" may be "cell death induction" or in our case "induction of apoptosis". All coefficients and required parameters are listed in Tab. 1 and Tab. 2.
It depends on the experimental design whether [10] is useful or not. For clonogenic assays in vitro or growth delay experiments in vivo one should actually use linear-quadratic approaches.
One must keep in mind that the used equations describe extrapolated curves which try to predict the effect for doses which cannot be tested (so it is more reliable to use an established model).
Now one has to evaluate all calculated equations. The result is a set of 22 implicitly given surfaces which can be plotted.
With respect to [10] one has to remark that some of the equations are identical (as f_{3} is linear).
The corresponding solutions in an explicit manner will be of the form x_{k} = g(x_{i}, x_{j}). Beside the three-dimensional representation it will be useful to plot the cuts through the point (d_{1}|d_{2}|d_{3}). This is easily performed by setting x_{i} = d_{i}, i ∈ {1, 2, 3}.
Here are some of the solutions (the number of the formula with a star corresponds to the above mentioned equation without star):
${\text{x}}_{3}=\frac{1}{{\text{a}}_{3}}\left(-{\text{b}}_{1}-{\text{b}}_{2}-{\text{b}}_{3}+\text{i}-{\text{a}}_{1}\mathrm{ln}{\text{x}}_{1}-{\text{a}}_{2}\mathrm{ln}{\text{x}}_{2}\right)[{2}^{*}]$
${\text{x}}_{3}=\frac{1}{{\text{a}}_{3}}\left(-{\text{b}}_{1}-{\text{b}}_{2}+{\text{b}}_{3}+\text{i}-{\text{a}}_{1}\mathrm{ln}{\text{x}}_{1}-{\text{a}}_{2}\mathrm{ln}{\text{x}}_{2}\right)[{3}^{*}]$
${\text{x}}_{3}=\frac{1}{{\text{a}}_{3}}\left(\text{i}-{\text{b}}_{2}-{\text{a}}_{2}\mathrm{ln}\left({\text{e}}^{\frac{1}{{\text{a}}_{2}}\left({\text{a}}_{1}\mathrm{ln}{\text{x}}_{1}+{\text{b}}_{1}-{\text{b}}_{2}\right)}+{\text{x}}_{2}\right)\right)[{4}^{*}]$
${\text{x}}_{3}=\frac{1}{{\text{a}}_{3}}\left(\text{i}-{\text{b}}_{1}-{\text{a}}_{1}\mathrm{ln}\left({\text{e}}^{\frac{1}{{\text{a}}_{1}}\left({\text{a}}_{2}\mathrm{ln}{\text{x}}_{2}+{\text{b}}_{2}-{\text{b}}_{1}\right)}+{\text{x}}_{1}\right)\right)\text{}[{5}^{*}]$
${\text{x}}_{3}=\frac{1}{{\text{a}}_{3}}\left(\text{i}-{\text{b}}_{2}-{\text{b}}_{3}-{\text{a}}_{2}\mathrm{ln}\left({\text{e}}^{\frac{1}{{\text{a}}_{2}}\left({\text{a}}_{1}\mathrm{ln}{\text{x}}_{1}+{\text{b}}_{1}-{\text{b}}_{2}\right)}+{\text{x}}_{2}\right)\right)[{6}^{*}]$
${\text{x}}_{3}=\frac{1}{{\text{a}}_{3}}\left(\text{i}-{\text{b}}_{1}-{\text{b}}_{3}-{\text{a}}_{1}\mathrm{ln}\left({\text{e}}^{\frac{1}{{\text{a}}_{1}}\left({\text{a}}_{2}\mathrm{ln}{\text{x}}_{2}+{\text{b}}_{2}-{\text{b}}_{1}\right)}+{\text{x}}_{1}\right)\right)[{7}^{*}]$
${\text{x}}_{3}=\frac{1}{{\text{a}}_{3}}\left(\text{i}-{\text{b}}_{1}-{\text{b}}_{2}-{\text{a}}_{1}\mathrm{ln}{\text{x}}_{1}-{\text{a}}_{2}\mathrm{ln}{\text{x}}_{2}\right)[{8}^{*}]$
[8] and [9] have an identical solution because of the above mentioned linearity of f_{3}. Overall, there are 5 equations which are redundant so that there are 17 distinct surfaces at the end.
Some of the surfaces have no real solutions in certain domains of the space. In these special cases a 2D representation helps to decide whether the point of therapy lies in the domain of synergism or not.
It can be shown that the solutions are unique (which is a consequence of the bijective attempt [10]). This proof would be beyond the scope of the paper.
It is interesting that in Fig. 4 there seem to be less curves than equations. There are two simple reasons: 1) some equations are identical as mentioned above, 2) some equations produce different results but are very similar to other equations so that they cannot be differentiated visually.
We provide (as a supplement to this paper) two small programmes which the reader can use for his own experimental data (a detailed description is also included) [see Additional files 1, 2 and 3].
Statistics
Similar as for two-dimensional isobolograms [9] a separate statistical analysis is required in our case. As one assumes the regression curves for the agents/XRT to be "exact", it is possible to calculate a new isobologram which corresponds to the lower limit of the 95 % confidence interval of the isodose (which corresponds to [i - 1,96 × SEM]). So we are able to elucidate if the triple remains synergistic. In this case we would be allowed to call the synergism "significant".
Discussion
Starting from the semantic definition of "synergy" and the problem to evaluate a combination of three modalities we developed a system of 22 equations which enable the user to derive the correct type of interaction.
This is a new aspect according to the classically used "combination index" [10] which only focuses on one of the 22 surfaces.
From the reported theory the following may be obtained:
1) It leads to a far wider concept of additivity. Thus it is important to define what definition is used.
2) It is often difficult to get out the mechanisms on the molecular layer but isobologram analysis has managed to handle these combined therapies and allows to deduce some of the biological effects behind the therapy.
This means that a synergism can under certain circumstances be a useful tool to elicit which combinations might make sense for clinical trials.
For this purpose strict conditions should be set up to determine which one of the combinations is really promising. The given equations (in their general form) provide the necessary mathematical formalism for this purpose.
One problem remains: how can we decide whether a given triple therapy acts in a "more synergistic" way than a combination of just two modalities?
It was only shown that the triple therapy is synergistic with respect to the effects of the single modalities. When using isobologram analysis there is no other possibility as a double combination is not feasible as a free parameter.
Materials and methods
Coefficients for the parametric representations of the dose-response-relationships
a _{1} | a _{2} | a _{3} | b _{1} | b _{2} | b _{3} |
---|---|---|---|---|---|
8.5 | 2.0 | 3.1 | 65.6 | 4.3 | 3.1 |
Doses for the triple therapy RT + A + B and level of isodose
i [%] | d _{1} [μg/ml] | d _{2} [nM] | d _{3} [Gy] |
---|---|---|---|
52 | 0.001 | 1 | 5 |
Declarations
Acknowledgements
Supported by a grant from the Federal Ministry of Education and Research (Fö. 1548-0-0) and the Interdisciplinary Center of Clinical Research Tübingen (IZKF).
Authors’ Affiliations
References
- Berenbaum MC: A method for testing for synergy with any number of agents. J Infect Dis 1978,137(2):122-130.View ArticlePubMedGoogle Scholar
- Berenbaum MC: What is synergy? Pharmacol Rev 1989,41(2):93-141.PubMedGoogle Scholar
- Bliss CI: The toxicity of poisons applied jointly. Ann Appl Biol 1939, 26: 585–615.View ArticleGoogle Scholar
- Krause M, Schutze C, Petersen C, Pimentel N, Hessel F, Harstrick A, Baumann M: Different classes of EGFR inhibitors may have different potential to improve local tumour control after fractionated irradiation: a study on C225 in FaDu hSCC. Radiother Oncol 2005,74(2):109-115. 10.1016/j.radonc.2004.10.011View ArticlePubMedGoogle Scholar
- Loewe S, Muischnek H: Effect of combinations: mathematical basis of the problem. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol 1926, 114: 313-326. 10.1007/BF01952257View ArticleGoogle Scholar
- Mohi MG, Boulton C, Gu TL, Sternberg DW, Neuberg D, Griffin JD, Gilliland DG, Neel BG: Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci U S A 2004,101(9):3130-3135. 10.1073/pnas.0400063101PubMed CentralView ArticlePubMedGoogle Scholar
- Pfister DG, Su YB, Kraus DH, Wolden SL, Lis E, Aliff TB, Zahalsky AJ, Lake S, Needle MN, Shaha AR, Shah JP, Zelefsky MJ: Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol 2006,24(7):1072-1078. 10.1200/JCO.2004.00.1792View ArticlePubMedGoogle Scholar
- Steel GG, Peckham MJ: Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 1979,5(1):85-91.View ArticlePubMedGoogle Scholar
- Tallarida RJ: Drug synergism: its detection and applications. J Pharmacol Exp Ther 2001,298(3):865-872.PubMedGoogle Scholar
- Tallarida RJ: The interaction index: a measure of drug synergism. Pain 2002,98(1-2):163-168. 10.1016/S0304-3959(02)00041-6View ArticlePubMedGoogle Scholar
Copyright
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate. Please note that comments may be removed without notice if they are flagged by another user or do not comply with our community guidelines.